These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27096597)

  • 21. A mechanism-driven treatment for chronic lymphocytic leukemia?
    Foà R; Guarini A
    N Engl J Med; 2013 Jul; 369(1):85-7. PubMed ID: 23782159
    [No Abstract]   [Full Text] [Related]  

  • 22. Highlights in chronic lymphocytic leukemia from the 60th American Society of Hematology Annual Meeting.
    Clin Adv Hematol Oncol; 2019 Jan; 17 Suppl 1(1):1-24. PubMed ID: 31545307
    [No Abstract]   [Full Text] [Related]  

  • 23. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.
    Wierda WG; Byrd JC; O'Brien S; Coutre S; Barr PM; Furman RR; Kipps TJ; Burger JA; Stevens DA; Sharman J; Ghia P; Flinn IW; Zhou C; Ninomoto J; James DF; Tam CS
    Br J Haematol; 2019 Jul; 186(1):184-188. PubMed ID: 30740654
    [No Abstract]   [Full Text] [Related]  

  • 24. [Chronic Lymphocytic Leukemia. New targeted therapy option Ibrutinib].
    Bruhn C
    Med Monatsschr Pharm; 2014 Jul; 37(7):268-9. PubMed ID: 25065170
    [No Abstract]   [Full Text] [Related]  

  • 25. Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.
    Boudin L; Patient M; Tsitsi Nding Tsogou P; Roméo E; Bladé JS; de Jauréguiberry JP
    Bull Cancer; 2019 Jan; 106(1):84-85. PubMed ID: 30579570
    [No Abstract]   [Full Text] [Related]  

  • 26. Spuriously low lymphocyte count associated with pseudoerythroblastemia in a patient with chronic lymphocytic leukemia treated with ibrutinib.
    Robier C; Beham-Schmid C; Neubauer M
    Clin Chem Lab Med; 2018 Apr; 56(5):e112-e114. PubMed ID: 29252190
    [No Abstract]   [Full Text] [Related]  

  • 27. Resolution of eosinophilia and elevated immunoglobulin E with ibrutinib for chronic lymphocytic leukemia.
    Harada K; Brooks JP; Lobo FM
    Ann Allergy Asthma Immunol; 2018 Nov; 121(5):629-630.e1. PubMed ID: 30009879
    [No Abstract]   [Full Text] [Related]  

  • 28. Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
    Lenz G
    J Clin Oncol; 2017 May; 35(13):1451-1452. PubMed ID: 28291389
    [No Abstract]   [Full Text] [Related]  

  • 29. The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
    van der Straten L; Levin MD; Visser O; Blijlevens NMA; Cornelissen JJ; Doorduijn JK; Kater AP; Dinmohamed AG
    Br J Haematol; 2020 Mar; 188(6):e109-e112. PubMed ID: 31991479
    [No Abstract]   [Full Text] [Related]  

  • 30. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
    Ambinder AJ; Hambley B; Shanbhag S; Merrill SA
    Am J Hematol; 2019 Nov; 94(11):E296-E299. PubMed ID: 31400009
    [No Abstract]   [Full Text] [Related]  

  • 31. Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia.
    Gohil SH; Evans R; Harasser M; El-Kholy M; Paredes-Moscosso SR; Della Peruta M; Nathwani AC
    Br J Haematol; 2019 Jul; 186(2):380-382. PubMed ID: 30957227
    [No Abstract]   [Full Text] [Related]  

  • 32. Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.
    England JT; Leitch HA
    Leuk Lymphoma; 2018 Mar; 59(3):752-754. PubMed ID: 28728450
    [No Abstract]   [Full Text] [Related]  

  • 33. Management of hypogammaglobulinemia and recurrent infections in a chronic lymphocytic leukemia patient receiving ibrutinib.
    Jiang F; Verma P
    Ann Allergy Asthma Immunol; 2018 Mar; 120(3):324-325. PubMed ID: 29174859
    [No Abstract]   [Full Text] [Related]  

  • 34. Haematological cancer: Ibrutinib supercharges CAR T cells.
    Sidaway P
    Nat Rev Clin Oncol; 2016 Apr; 13(4):204. PubMed ID: 26880473
    [No Abstract]   [Full Text] [Related]  

  • 35. Hope for high-risk chronic lymphocytic leukemia relapsing after allogeneic stem-cell transplantation.
    Montserrat E; Dreger P
    J Clin Oncol; 2015 May; 33(14):1527-9. PubMed ID: 25870086
    [No Abstract]   [Full Text] [Related]  

  • 36. Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).
    Chanan-Khan A; Egyed M; Robak T; Martinelli de Oliveira FA; Echeveste MA; Dolan S; Desjardins P; Blonski JZ; Mei J; Golany N; Zhang J; Gribben JG
    Leukemia; 2017 May; 31(5):1240-1243. PubMed ID: 28140392
    [No Abstract]   [Full Text] [Related]  

  • 37. Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib.
    Shumilov E; Wulf G; Ströbel P; Hasenkamp J; Hellige N; Bleckmann A; Haase D; Braulke F; Jung W; Schanz J; Binder M; Trümper L; Bacher U
    Leuk Lymphoma; 2016 Oct; 57(10):2476-80. PubMed ID: 26916814
    [No Abstract]   [Full Text] [Related]  

  • 38. Ibrutinib: targeting the hidden CLL.
    Awan FT
    Blood; 2014 May; 123(21):3215-6. PubMed ID: 24855190
    [No Abstract]   [Full Text] [Related]  

  • 39. Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program.
    Hillmen P; Diels J; Healy N; Iraqi W; Aschan J; Wildgust M
    Haematologica; 2018 May; 103(5):e204-e206. PubMed ID: 29419428
    [No Abstract]   [Full Text] [Related]  

  • 40. [Cryptococcal meningitis in the treatment of CLL with ibrutinib: a case report and literature review].
    Zhang H; Zhang XH; Chen P; Li BZ
    Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):428-430. PubMed ID: 32536143
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.